3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 3
3
Phase 1/2
2
Phase 1
2
Status
Active not recruiting
5
Recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Carcinoma, Renal Cell
3
von Hippel-Lindau Disease
1
Carcinoma
1
Interventions
Carboplatin
98
Cisplatin
95
pembrolizumab
90
Gemcitabine
81
Paclitaxel
80
Docetaxel
73
Capecitabine
64
Oxaliplatin
53
Specimen Handling
52
Fluorouracil
52
Magnetic Resonance Spectroscopy
50
Bevacizumab
49
Radiotherapy
48
Dexamethasone
45
Cyclophosphamide
44
Leucovorin
39
Drug Therapy
39
Irinotecan
37
Doxorubicin
36
Pemetrexed
35
Injections
30
Trastuzumab
28
Vincristine
27
Rituximab
27
Radiosurgery
25
Prednisone
25
Etoposide
25
130-nm albumin-bound paclitaxel
25
Radiation
24
Letrozole
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Recruiting
×
belzutifan
×
Clear all
NCT07227402
2026-06-04
LITESPARK-033
Merck Sharp & Dohme LLC
Phase 3
Recruiting
904 enrolled
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled
NCT07489495
2026-05-29
LITESPARK-034
Merck Sharp & Dohme LLC
Phase 3
Recruiting
758 enrolled